Condition
ARID1A Gene Mutation
Total Trials
5
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
5Total
P 1 (2)
P 2 (3)
Trial Status
Terminated2
Recruiting2
Active Not Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT05023655Phase 2Terminated
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
NCT05490472Phase 1Recruiting
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT06518564Phase 2Recruiting
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
NCT05226507Phase 1Active Not Recruiting
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
NCT05523440Phase 2Terminated
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
Showing all 5 trials